Biological markers or commonly referred to as biomarkers are biological measures or medical signs which can be measured accurately and reproducibly in patients. Examples of biomarkers can be anything from pulse and blood pressure to more complex blood tests and other tissues. There are different types of biomarkers including systemic and molecular biomarkers and the investigation of these provide potential targets for developing osteoarthritis disease-modifying drugs.

On this episode of Joint Action, we are joined by Virginia Kraus to discuss the role of biomarkers in osteoarthritis and in particularly their role in drug development.

Virginia Kraus is a Professor of Medicine at the Duke University School of Medicine. She is a practicing Rheumatologist with over 20 years experience in musculoskeletal research focusing on osteoarthritis. She is an adjunct Professor of Pathology and an adjunct Associate Professor of Surgery. Her career has focused on elucidating osteoarthritis pathogenesis and translational research into the discovery and validation of biomarkers for early osteoarthritis detection, prediction of progression, and monitoring of disease status.

Listen to Virginia and The Women's Voices Chorus here.

CONNECT WITH US

• Twitter: @ProfDavidHunter @jointactionorg
• Email: hello@jointaction.info
• Website: www.jointaction.info/podcast

If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts!

Hosted on Acast. See acast.com/privacy for more information.